|Bid||0.00 x 800|
|Ask||120.90 x 1300|
|Day's Range||118.01 - 121.77|
|52 Week Range||89.62 - 150.06|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||48.32|
|Earnings Date||Jul 22, 2020 - Jul 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 02, 1998|
|1y Target Est||131.88|
Varian (NYSE: VAR) today announced it received the "Best After-Sales Service Award for Radiotherapy Products" in the 2019 Chinese Medical Devices Industry Data and After-Sales Service Survey for the third year in a row. Varian also led in metrics of Market Share, Repurchasing Reference, and Net Promoter Score.
Dr. Cipto Mangunkusumo Hospital, Jakarta has become the first hospital in Indonesia to treat patients using Varian's Halcyon™ system. The first patient, a 14 year old female, was treated for Hodgkin lymphoma.
Long-term results of the Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Cancers (SABR-COMET) study published June 2, 2020 in the Journal of Clinical Oncology showed positive increases in overall survival for patients with multiple sites of metastasis when treated with stereotactic ablative radiotherapy (SABR) versus standard-of-care.1 Through the extended follow-up, the impact of SABR on overall survival was larger in magnitude than in the study's initial analysis published last year in The Lancet.2
In this article we will check out the progression of hedge fund sentiment towards Varian Medical Systems, Inc. (NYSE:VAR) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 […]
Varian Medical Systems shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Varian (NYSE: VAR) today announced two executive appointments. Michael Hutchinson has joined the company as Senior Vice President, Chief Legal Officer following the previously communicated retirement plans of John Kuo. The company also announced that Francis (Frank) R. Facchini, M.D., FSIR has assumed a permanent role as President of Varian's Interventional Solutions (IS) business, effective immediately.
Varian (NYSE: VAR) today announced that Dow Wilson, Chief Executive Officer, J. Michael Bruff, Chief Financial Officer, and Anshul Maheshwari, Vice President, Investor Relations and Treasurer will participate in a virtual fireside chat at the Goldman Sachs Global Virtual Healthcare Conference, scheduled for 11:20 a.m. Eastern Time on Tuesday, June 9, 2020.
Varian (NYSE: VAR) today announced that J. Michael Bruff, Chief Financial Officer, Chris Toth, President, Varian Oncology Systems, and Anshul Maheshwari, Vice President, Investor Relations and Treasurer will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference, scheduled for 11:00 a.m. Eastern Time on Tuesday, June 2, 2020.
In response to the significant healthcare delivery changes brought on by COVID-19, Varian (NYSE: VAR) has launched new capabilities for its Noona® software application, a powerful tool designed to engage cancer patients in their care for continuous reporting and symptom monitoring. Noona supports cancer care teams as they face new short- and long-term healthcare changes created by the pandemic by providing in-app features such as patient screening, real-time symptom reporting, secure care team messaging, telephone triage workflow automation, and patient access to medical records. In addition, Varian has designed a new approach to quickly and remotely implement the solution to put it in the hands of cancer patients and care teams faster, without increasing the risk of COVID-19 exposure.
As further evidence of the strong industry response to a potential new paradigm in the treatment of cancer, Varian (NYSE: VAR) today announced that Proton Therapy Pte., Ltd. (http://www.proton.sg/) in Singapore has joined the FlashForward™ Consortium. Now including 20 members, representing nine countries, the Consortium is focused on preclinical research, clinical implementation, and advocacy efforts of FLASH therapy.
With its stock down 22% over the past three months, it is easy to disregard Varian Medical Systems (NYSE:VAR). But if...
Varian (NYSE: VAR) today announced that Dow Wilson, Chief Executive Officer, J. Michael Bruff, Chief Financial Officer, and Anshul Maheshwari, Vice President, Investor Relations and Treasurer, will participate in a virtual fireside chat at the UBS Virtual Global Healthcare Conference at 1:20 p.m. EDT on Monday, May 18, 2020.
Varian (NYSE: VAR) and the National University Cancer Institute, Singapore (NCIS), are partnering to expand access to cancer solutions in Singapore in the fight against cancer. In 2018, 26,164 cases of cancer were diagnosed in Singapore, and it is expected to more than double to 57,319 cases over the next 20 years.1
Swedish radiation therapy equipment maker Elekta on Tuesday slashed its sales growth and margin forecasts for the fiscal year ending in April, citing the impact of the COVID-19 pandemic. The company, which rivals U.S group Varian Medical Systems , said it now forecast constant currency sales growth of around 1% for the year, compared to its previous forecast of 8-10% growth, given in February. Elekta also forecast an operating margin (EBITA) of 16-17%, down from the 18% previously seen.
In 2012, Dow Wilson was appointed CEO of Varian Medical Systems, Inc. (NYSE:VAR). This analysis aims first to contrast...
The Icon Cancer Centre Wahroonga in Australia has treated its first cancer patient with Varian Ethos™. This artificial intelligence (AI)-driven holistic adaptive therapy solution is designed to deliver an entire adapted treatment in a typical 15-minute timeslot.
This week we saw the Varian Medical Systems, Inc. (NYSE:VAR) share price climb by 12%. But that doesn't change the...
Belgian medical technology therapy company Ion Beam Applications reported a small annual core profit on Thursday, meeting its guidance after its first six months ended in the red, and said it faced continued pricing pressure as rivals attempted to gain market share. The group, which makes machines that deliver cancer-fighting proton beams, a super precise form of radiation, made a full-year profit before interest and taxes (REBIT) of 87,000 euros ($94,986.60), after a profit of 5.7 million euros a year earlier. The company, which had forecast a positive REBIT, said the results reflected gross margin weakness as a result of pricing pressure on new contracts and greater investment in research and development, but cost cuts and controls helped mitigate that.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]